(:AMAR)
Business Focus: N/A
Jun 14, 2021 05:20 pm ET
Ainos Named Exclusive Sales Partner for COVID-19 Antigen Rapid Test Kit in Taiwan
SAN DIEGO, CA / ACCESSWIRE / June 14, 2021 / Ainos, Inc. ('we', 'our', or the 'Company'), (OTC PINK:AIMD), entered into an exclusive agreement to serve as the master sales and marketing agent for the Ainos SARS-CoV-2 Antigen Rapid Test Kit ("Covid-19 Test Kit") for Taiwan Carbon Nano Corporation ('TCNT').
May 24, 2021 10:40 am ET
Ainos Announces FINRA Approval of Name Change and Ticker Symbol Change to "AIMD", Engages Firm to Explore Listing Requirements of National Securities Exchanges
SAN DIEGO, CA / ACCESSWIRE / May 24, 2021 / Ainos, Inc., f/k/a Amarillo Biosciences, Inc. ("we", "our", or the "Company"), (OTC PINK:AIMD), is pleased to announce that the Financial Industry Regulatory Authority, Inc. ("FINRA") approved the Company's name change to "Ainos, Inc." and "AIMD" as its new ticker symbol.
Apr 21, 2021 02:25 pm ET
Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."
AMARILLO, TX / ACCESSWIRE / April 21, 2021 / Ainos, Inc., f/k/a Amarillo Biosciences, Inc. ("we" or the "Company"), (OTCBB:AMAR), a company engaged in the discovery and development of pharmaceutical and biotech products, announced today that it has consummated the transaction pursuant to that certain Securities Purchase Agreement ("Agreement") dated December 24, 2020 with a strategic investor, Ainos, Inc., a Cayman Islands corporation (the "Investor" or "Ainos KY") focused on advanced technology diagnostic medical device
Dec 30, 2020 02:05 pm ET
Amarillo Biosciences, Ind. Enters into a Securities Purchase Agreement to Foster New Growth
AMARILLO, TX / ACCESSWIRE / December 30, 2020 / Amarillo Biosciences, Inc. ("we," "ABI" or the "Company"), (OTC PINK:AMAR), a company engaged in low-dose non-injectable interferon research, announced today that it has entered into a Securities Purchase Agreement ("Agreement") with a strategic investor, Ainos, Inc., a Cayman Islands corporation ("Ainos") focused on advanced technology diagnostic medical devices and artificial intelligence consumer healthcare solutions. Ainos develops and manufactures point-of-care testing ("
Sep 10, 2020 01:21 pm ET
Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board
via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), the world leader in low-dose non-injectable interferon research, is pleased to announce the appointment of Dr. Manfred Beilharz, Associate Professor at The University...
Aug 13, 2020 02:46 pm ET
Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics
via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that it is taking steps to reaffirm its position as the world leader in low-dose non-injectable interferon research....
Feb 13, 2020 12:56 pm ET
Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications
via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that its China licensing partner, Xiamen Weiyang Pharmaceutical Co., Ltd. (“Xiamen Weiyang”), has begun initiating...
Jul 29, 2019 10:54 am ET
Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement
via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (OTCBB: AMAR), a diversified healthcare company, today announced that it has entered into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang...
Aug 23, 2018 09:00 am ET
Amarillo Biosciences First-Half 2018 Business Update
via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (ABI), (OTCBB: AMAR), a diversified healthcare company, today provided an update on its first-half 2018 results and recent business activities. “These past several quarters have continued to be an...
Sep 06, 2017 09:30 am ET
Amarillo Biosciences, Inc. Announces Investor Update
Amarillo Biosciences, Inc. (ABI) (OTC PINK: AMAR) has identified certain goals for its future business development, and wishes to share this information with both its shareholders and the general public. ABI recognizes that it needs to create new products and get them to market, monetize and commercialize its intellectual property, leverage core technology, and develop research capabilities to become an integrated healthcare enterprise of global distinction. Additionally, ABI must transform itself from the historically narrow focus in biotechnology to a wide variety of development
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.